Enzon Inc. of South Plainfield, N.J. and Porton Products Ltd. ofthe United Kingdom have signed the first of many agreementsto evaluate the use of Enzon's proprietary Pegnologytechnology to modify and enhance proteins developed byPorton, Enzon (NASDAQ:ENZN) announced Thursday. Terms ofthe agreement were not disclosed.
Pegnology technology couples polyethylene glycol (PEG) strandsto proteins, with the aim of extending their duration in thebloodstream and reducing their toxicity.
The agreement expands Enzon's Pegnology collaborationsoverseas and adds to Pegnology agreements with otherbiotechnology companies including Amgen Inc., AllelixBiopharmaceuticals Inc., Schering Corp.,Genelabs TechnologiesInc., Cytoclonal Pharmaceuticals Inc. and EmisphereTechnologies.
(c) 1997 American Health Consultants. All rights reserved.